Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

NCT05269316 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Advanced Solid Tumor

Interventions

DRUG: IMP9064

Sponsor

Impact Therapeutics, Inc.